Hyoscyamine Sulfate


Bpi Labs Llc
Human Prescription Drug
NDC 54288-111
Hyoscyamine Sulfate is a human prescription drug labeled by 'Bpi Labs Llc'. National Drug Code (NDC) number for Hyoscyamine Sulfate is 54288-111. This drug is available in dosage form of Injection, Solution. The names of the active, medicinal ingredients in Hyoscyamine Sulfate drug includes Hyoscyamine Sulfate - .5 mg/mL . The currest status of Hyoscyamine Sulfate drug is Active.

Drug Information:

Drug NDC: 54288-111
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Hyoscyamine Sulfate
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Hyoscyamine Sulfate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Bpi Labs Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Injection, Solution
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:HYOSCYAMINE SULFATE - .5 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:SUBCUTANEOUS
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED DRUG OTHER
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 18 Oct, 2019
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 20 Jan, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:BPI Labs LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1047916
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0354288111010
UPC stands for Universal Product Code.
UNII:F2R8V82B84
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
54288-111-055 VIAL in 1 CARTON (54288-111-05) / 1 mL in 1 VIAL (54288-111-01)18 Oct, 2019N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Hyoscyamine sulfate hyoscyamine sulfate water hyoscyamine sulfate hyoscyamine

Indications and Usage:

Indications and usage hyoscyamine sulfate injection, usp is effective as adjunctive therapy in the treatment of peptic ulcer. in acute episodes, hyoscyamine sulfate injection, usp can be used to control gastric secretion, visceral spasm and hypermotility in spastic colitis, spastic bladder, cystitis, pylorospasm, and associated abdominal cramps. for use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and functional gastrointestinal disorders. also as adjunctive therapy in the treatment of neurogenic bladder and neurogenic bowel disturbances (including the splenic flexure syndrome and neurogenic colon). parenterally administered hyoscyamine sulfate injection, usp is also effective in reducing gastrointestinal motility to facilitate diagnostic procedures such as endoscopy or hypotonic duodenography. hyoscyamine sulfate injection, usp may be used to reduce pain and hypersecretion in pancreatitis, in certain cases of parti
al heart block associated with vagal activity, and as an antidote for poisoning by anticholinesterase agents. in anesthesia: hyoscyamine sulfate injection, usp is indicated as a pre-operative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions, to reduce the volume and acidity of gastric secretions, and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. hyoscyamine sulfate injection, usp protects against the peripheral muscarinic effects such as bradycardia and excessive secretions produced by halogenated hydrocarbons and cholinergic agents such as physostigmine, neostigmine, and pyridostigmine given to reverse the actions of curariform agents. in urology: hyoscyamine sulfate injection, usp may also be used intravenously to improve radiologic visibility of the kidneys. it is also indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic.

Warnings:

Warnings in the presence of high environmental temperature, heat prostration can occur with drug use (fever and heat stroke due to decreased sweating). diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. in this instance, treatment with this drug would be inappropriate and possibly harmful. like other anticholinergic agents, hyoscyamine sulfate injection, usp may produce drowsiness or blurred vision. in this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery or to perform hazardous work while taking this drug. psychosis has been reported in sensitive individuals given anticholinergic drugs. cns signs and symptoms include confusion, disorientation, short term memory loss, hallucinations, dysarthria, ataxia, coma, euphoria, decreased anxiety, fatigue, insomnia, agitation and mannerisms, and inappropriate affect. these cns sign
s and symptoms usually resolve within 12 to 48 hours after discontinuation of the drug.

Dosage and Administration:

Dosage and administration the dose may be administered subcutaneously, intramuscularly, or intravenously without dilution. as with all parenteral drug products, hyoscyamine sulfate injection, usp should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. gastrointestinal disorders: the usual adult recommended dose is 0.5 to 1 ml (0.25 to 0.5 mg). some patients may need only a single dose; others may require administration two, three, or four times a day at four hour intervals. diagnostic procedures: the usual adult recommended dose is 0.5 to 1 ml (0.25 to 0.5 mg) administered intravenously 5 to 10 minutes prior to the diagnostic procedure. anesthesia: adults and pediatric patients over 2 years of age: as a pre-anesthetic medication, the recommended dose is 5 µg (0.005 mg) per kg of body weight. this dose is usually given thirty to sixty minutes prior to the anticipated time of induction of anesthesia or at th
e time the pre-anesthetic narcotic or sedatives are administered. hyoscyamine sulfate injection, usp may be used during surgery to reduce drug-induced bradycardia. it should be administered intravenously in increments of 0.25 ml and repeated as needed. to achieve reversal of neuromuscular blockade, the recommended dose is 0.2 mg (0.4 ml) hyoscyamine sulfate injection usp for every 1 mg neostigmine or the equivalent dose of physostigmine or pyridostigmine.

Contraindications:

Contraindications glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis); paralytic ileus, intestinal atony of elderly or debilitated patients; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis and myocardial ischemia.

Adverse Reactions:

Adverse reactions not all of the following adverse reactions have been reported with hyoscyamine sulfate. the following adverse reactions have been reported for pharmacologically similar drugs with anticholinergic/antispasmodic action. adverse reactions may include dryness of the mouth; urinary hesitancy and retention; blurred vision; tachycardia; palpitations; mydriasis; cycloplegia; increased ocular tension; loss of taste; headache; nervousness; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; impotence; suppression of lactation; constipation; bloated feeling; allergic reactions or drug idiosyncrasies; urticaria and other dermal manifestations; ataxia; speech disturbance; some degree of mental confusion and/or excitement (especially in elderly persons); and decreased sweating. to report suspected adverse reactions, contact bpi labs, llc, at (727-471-0850) or fda at 1-800-fda-1088 or www.fda.gov/medwatch.

Overdosage:

Overdosage the signs and symptoms of overdose are headache, nausea, vomiting, blurred vision, dilated pupils, hot dry skin, dizziness, dryness of the mouth, difficulty in swallowing, and cns stimulation. measures to be taken are immediate lavage of the stomach and injection of physostigmine 0.5 to 2 mg intravenously and repeated as necessary up to a total of 5 mg. fever may be treated symptomatically (tepid water sponge baths, hypothermic blanket). excitement to a degree which demands attention may be managed with sodium thiopental 2% solution given slowly intravenously or chloral hydrate (100 to 200 ml of a 2% solution) by rectal infusion. in the event of progression of the curare-like effect to paralysis of the respiratory muscles, artificial respiration should be instituted and maintained until effective respiratory action returns. in rats, the ld 50 for hyoscyamine is 375 mg/kg. hyoscyamine sulfate injection, usp is dialyzable.

Description:

Description hyoscyamine sulfate injection, usp is a sterile solution containing 0.5 mg hyoscyamine sulfate per ml in water for injection. hyoscyamine sulfate injection, usp is one of the principal anticholinergic/antispasmodic components of belladonna alkaloids. the empirical formula is (c 17 h 23 no 3 ) 2 •h 2 so 4 •2h 2 0 and the molecular weight is 712.85. chemically, it is benzeneacetic acid, α-(hydroxymethyl)-,8-methyl-8-azabicyclo [3.2.1.] oct-3-yl ester, [3(s)-endo]-, sulfate (2:1), dihydrate with the following structure: the 1 ml vials contain as inactive ingredients: water for injection, ph is adjusted with hydrochloric acid when necessary. structure

Clinical Pharmacology:

Clinical pharmacology hyoscyamine sulfate injection, usp inhibits specifically the actions of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. these peripheral cholinergic receptors are present in the autonomic effector cells of the smooth muscle, cardiac muscle, the sinoatrial node, the atrioventricular node, and the exocrine glands. it is completely devoid of any action in the autonomic ganglia. hyoscyamine sulfate injection, usp inhibits gastrointestinal propulsive motility and decreases gastric acid secretion. hyoscyamine sulfate injection, usp also controls excessive pharyngeal, tracheal and bronchial secretions. hyoscyamine sulfate injection, usp disappears rapidly from the blood and is distributed throughout the entire body. the half-life of hyoscyamine sulfate injection, usp is 31/2 hours. hyoscyamine sulfate injection, usp is partly hydrolyzed to tropic acid and tro
pine but the majority of the drug is excreted in the urine unchanged within the first 12 hours. only traces of this drug are found in breast milk. hyoscyamine sulfate injection, usp passes the blood brain barrier and the placental barrier.

How Supplied:

How supplied hyoscyamine sulfate injection usp (hyoscyamine sulfate injection usp, 0.5 mg/ml), is available in 1 ml vials. 1 ml vials – box of 5 ndc 54288-111-05 store at 25°c (77°f); excursions permitted to 15° to 30°c (59° to 86°f) [see usp controlled room temperature]. also available as: product dosage strength package size ndc hyoscyamine sulfate injection, usp 0.5 mg/ml 5 vials (1 ml each) 54288-111-05

Package Label Principal Display Panel:

Principal display panel – 0.5 mg/ml ndc 54288-111-01 hyoscyamine sulfate injection, usp 0.5 mg hyoscyamine sulfate, usp per ml in water for injection. 5 vials (1 ml each) rx only dosage and administration: see package insert for further information. store at 25°c (77°f), excursions permitted to 15° to 30°c (59° to 86°f) [see usp controlled room temperature]. distributed by: bpi labs llc 12393 belcher rd s largo fl 33773 r-1907 li01i carton: ndc 54288-111-05 hyoscyamine sulfate injection, usp 0.5 mg hyoscyamine sulfate, usp per ml in water for injection. rx only vial carton


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.